puberty (male), delay 314
puerperium, anticoagulants 209
pulmonary blood flow, anaesthesia 146
pulmonary embolism, heparins for 205
pulmonary eosinophilia 243
pulmonary fibrosis
amiodarone 224
drugs causing 243
pulmonary oedema 211 , 213
heroin overdose 435
pulmonary surfactants 242
pupil 423
miosis 423, 425–6
see alsomydriasis
purine antimetabolites 376–7
purpura
drugs causing 418
idiopathic thrombocytopenic 395
PUVA (psoralen with UVA light) 414–16
pyrazinamide 335
hepatotoxicity 263
pyridostigmine 130
pyridoxineseevitamin B 6
pyrimethamine
malaria 364
Toxoplasma gondii 358–9
pyrimidine antimetabolites 375
quadruple therapy, tuberculosis in HIV infection
359
quinidine, interaction with digoxin 73
quinine 363
pregnancy 48
quinolones 330–1
‘radiation recall’ 377
radioactive iodine 294–5
randomization, clinical trials 87–8
ranibizumab 428
ranitidine 249–51
ranitidine bismuth citrate tablets 251
rapid acetylators 80
rasagiline 127–8
rasburicase 173
rashes 68
ampicillin 55, 65
rate constant, for elimination (kel)13
re-entry tachycardia 218
reabsorption, renal 32–3, 76–7
receptor tyrosine kinase inhibitors 381
receptors 6–7
classifications 7
desensitization 9
polymorphisms 82–3
recombinant DNA therapies 92–6
recombinant factor VIII 92, 395
recombinant growth hormone 92, 316
recombinant haematopoietic growth factors
392–4
rectal route 20
children 54
diazepam 54, 140
‘red man’ syndrome 330
reduction of drugs (metabolic) 25
reflux oesophagitis 252
pregnancy 49
regulation of medicines, United Kingdom 86
rehabilitation, myocardial infarction 200
remifentanil 150, 161
renal artery stenosis, ACEIs 188
renal failure 35–7
from diuretics 280
on drug dosage 33
functional, ACEIs 188
methotrexate 375
repaglinide 289
repeated dosing, pharmacokinetics 13–14
reproductive endocrinology 307–15
hormone antagonists 312
research
children 55
clinical trials 5, 64, 86–8, 89–90
elderly patients 60
see alsodrug development
resins, ion-exchange 181 , 182, 279
resistance
to antibiotics 324–5
to azoles 341
to cytotoxic drugs 369, 370
HIV to therapy 357
malaria to chloroquine 362
respiratory failure 241–2
resuscitation
cardiopulmonary 218–21
see alsosupportive therapy
reteplase 199, 202
retinitis, cytomegalovirus 359
retinoids 266
acitretin 416
acne 411–12
teratogenesis 412, 416
retinol (vitamin A) 265–6
retinopathy
chloroquine 362
diabetes mellitus 285–6
fibrinolysis and 203
reversible antagonism 8
Reye’s syndrome 54, 157
rhDNase (mucolytic) 242
rhesus-negative mothers, anti-D
immunoglobulin 408
ribavirin 347
riboflavin 392
rifabutin, protease inhibitors and 356
rifampicin 335, 336–7
ciclosporin and 402
fluconazole and 342
leprosy 339
on liver 262
protease inhibitors and 356
terbinafine and 343
theophylline and 239
riluzole 129
rimantadine 348
rimonabant 263
Ringer’s lactate solution 277
risedronate 299
risk/benefit 3–4
risperidone 114
ritonavir 356, 360
rituximab 383
rivastigmine 131–2
rizatriptan 143
rocuronium bromide 151
ropivacaine 153
rosiglitazone 290
rosuvastatin 180
ryanodine R1 receptor 83–4, 152SAHA (vorinostat) 382
salbutamol 21, 236–7
anaphylactic shock 405
respiratory failure 242
salicylates 157
on liver 262
methotrexate and 375
poisoning 448
salmeterol 237
saquinavir 356
sartansseeangiotensin receptor blockers
satiety factors 263
saturationenzymes 15
transferrin 390
saturation kinetics, phenytoin 136–7
saw palmetto 100
scabies 417
Schildt plots 9
schistosomiasis, drug for 366
schizophrenia 110–14
sciatic nerve, avoidance in intramuscular
injection 21
scurvy 267
seborrhoeic dermatitis 413
sedation, intensive care 150
seizures 133
children 54
ciclosporin 408
febrile 140
see alsoepilepsy
selective oestrogen receptor modulators and
downregulators 384
selective serotonin (5HT) reuptake inhibitors
117–18, 122
elderly patients 58
poisoning 448
selegiline 127–8
self-poisoning 444–9
sensitivity of receptors, manipulation 9–10
serology, adverse drug reactions 63
serotonin-noradrenaline reuptake inhibitors
(SNRI) 116, 118
serotonin-only hypothesis, depression 116
serum sickness 66
severe combined immunodeficiency disease,
gene therapy 95
sevoflurane 147
shingles, aciclovir 345
shock
anaphylaxis 404, 405, 406
volume depletion 277–8
shock lung 241
short stature 316
SIADH (syndrome of inappropriate antidiuretic
hormone) 276–7
sibutramine 263
sick sinus syndrome 223
signal transduction 8
sildenafil 315
azoles and 350
nitrates and 442
simvastatin 180, 182
Singh–Vaughan–Williams classification, anti-
dysrhythmic drugs 218, 219
single-bolus doses, pharmacokinetics 12–13
single nucleotide polymorphisms 79
sinus bradycardia 223
sirolimus 403
micafungin on 343
plasma concentration monitoring 43
skin 411–19
adverse drug reactions 66–7, 68
amiodarone 224
drug absorption 20–1, 22, 414
children 52, 54
provocation testing 63
sleep 105–7
elderly patients 58
slow-reacting substance of anaphylaxis 240
slow-release preparations 18, 20
aspirin 157
overdose 445
small intestine, disease on drug disposition
34
smoking 438–9
atheroma 179
peptic ulcer 248
pregnancy 50, 438INDEX 463